Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Items 301–400 of 864
Debrincat, M. A., Zhang, J.-G., Willson, T. A., Silke, J., Connolly, L. M., Simpson, R. J., Alexander, W. S., Nicola, N. A., Kile, B. T., & Hilton, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609164200 · Cited by 47
Nobel Committee Tags Ubiquitin for Distinction
Goldberg, A. L. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.019 · Cited by 49
Molecular genetics of gastroenteropancreatic neuroendocrine tumors
Starker, L. F., & Carling, T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328319ea7b · Cited by 46
The Molecular Biology of Renal Cell Carcinoma
O’Keefe, S. J., Nathanson, K. L., & Rathmell, W. K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.006 · Cited by 53
Hypoxia-inducible factors and cancer
Calzada, M. J., & del Peso, L. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0055-y · Cited by 58
Role of the NEDD8 Modification of Cul2 in the Sequential Activation of ECV Complex
Sufan, R. I., & Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06520 · Cited by 45
Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez, G., & Giuliani, A. (2007) · PubMed · Cited by 54
Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review
Slim, E. A., Antoun, J. S., Kourié, H. R., Schakal, A., & Cherfan, G. (2014) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.07.007 · Cited by 44
Harten, S. K., Esteban, M. A., Shukla, D., Ashcroft, M. A., & Maxwell, P. H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-89 · Cited by 54
All along the watchtower: Is the cilium a tumor suppressor organelle?
Mans, D. A., Voest, E. E., & Giles, R. H. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.002 · Cited by 48
Bussolati, B., Deregibus, M. C., & Camussi, G. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790887036 · Cited by 48
Evolution of VHL tumourigenesis in nerve root tissue
Vortmeyer, A., Tran, M. G. B., Zeng, W., Gläsker, S., Riley, C., Tsokos, M., Ikejiri, B. L., Merrill, M., Raffeld, M. A., Zhuang, Z., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2062 · Cited by 45
Chimeric Molecules to Target Proteins for Ubiquitination and Degradation
Sakamoto, K. M. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99054-x · Cited by 42
Ampofo, E., Kietzmann, T., Zimmer, A. D., Jakupović, M., Montenarh, M., & Götz, C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.07.008 · Cited by 41
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer
Zhang, Q. H., & Yang, H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00035 · Cited by 47
Pavesi, G., Feletti, A., Berlucchi, S., Opocher, G., Martella, M., Murgia, A., & Scienza, R. (2008) · PubMed · Cited by 41
Functional Subunits of Eukaryotic Chaperonin CCT/TRiC in Protein Folding
Kabir, M. A., Uddin, W., Narayanan, A., Reddy, P. K., Jairajpuri, M. A., Sherman, F., & Ahmad, Z. (2011) · Journal of Amino Acids · doi:10.4061/2011/843206 · Cited by 41
The von Hippel-Lindau Tumor Suppressor Protein Is a Molten Globule under Native Conditions
Sutovsky, H., & Gazit, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311225200 · Cited by 44
Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors
Asa, S. L., Rosa, S. L., Baştürk, O., Adsay, V. N., Minnetti, M., & Grossman, A. B. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09662-5 · Cited by 43
Tzouanacou, E., Tweedie, S., & Wilson, V. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8553-8562.2003 · Cited by 40
New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma
Taïeb, D., & Pacák, K. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.08.001 · Cited by 43
Pathophysiology and management of glaucoma associated with phakomatoses
Thavikulwat, A. T., Edward, D. P., AlDarrab, A., & Vajaranant, T. S. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24241 · Cited by 40
Wang, L., Liang, Y., Li, P., Liang, Q., Sun, H., Xu, D., & Hu, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s228522 · Cited by 43
Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma
Weaver, C., Satter, K. B., Richardson, K. P., Tran, L. K. H., Tran, P. M. H., & Purohit, S. B. (2022) · Biomedicines · doi:10.3390/biomedicines10112953 · Cited by 55
Chan, C., Chew, E. Y., Shen, D., Hackett, J., & Zhuang, Z. (2005) · PubMed · Cited by 43
Ding, X., Zhou, J., Hu, Q., Liu, S., & Chen, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589226 · Cited by 39
Xu, J., Wang, B., Xu, Y., Sun, L. X., Tian, W., Shukla, D., Barod, R., Grillari, J., Grillari‐Voglauer, R., Maxwell, P. H., et al. (2011) · Oncogene · doi:10.1038/onc.2011.305 · Cited by 44
U19/Eaf2 Binds to and Stabilizes von Hippel-Lindau Protein
Xiao, W., Ai, J., Habermacher, G. M., Volpert, O. V., Yang, X. J., Zhang, A.-Y., Hahn, J., Cai, X., & Wang, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2595 · Cited by 39
Cheng, L., Williamson, S. R., Zhang, S., MacLennan, G. T., Montironi, R., & López-Beltrán, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.72 · Cited by 38
lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
Bohošová, J., Kubíčková, A., & Slabý, O. (2021) · Biomolecules · doi:10.3390/biom11050664 · Cited by 39
Fielding, J. W., Hodson, E. J., Cheng, X., Ferguson, D. J. P., Eckardt, L., Adam, J., Lip, P. Z. Y., Maton‐Howarth, M., Ratnayaka, I., Pugh, C. W., et al. (2018) · Figshare · doi:10.17863/cam.40823 · Cited by 38
The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis
Hudler, P., & Urbančič, M. (2022) · Genes · doi:10.3390/genes13020362 · Cited by 47
Corgna, E., Betti, M., Gatta, G., Roila, F., & Mulder, P. H. M. D. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.007 · Cited by 38
Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance
Sakamoto, S., Ryan, A. J., & Kyprianou, N. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21442 · Cited by 44
B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features
Guipaud, O., Deriano, L., Salin, H., Vallat, L. D., Sabatier, L., Merle‐Béral, H., & Delić, J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01171-9 · Cited by 41
Gollob, J. (2005) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2005.n.028 · Cited by 42
Sakai, K., Fukuda, T., & Iwadate, K. (2013) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000067 · Cited by 39
Retinal Vascular Proliferation as an Ocular Manifestation of von Hippel-Lindau Disease
Wong, W. T. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.5.637 · Cited by 37
Griffin, M. E., Hamilton, B. J., Roy, K., Du, M., Willson, A. M., Keenan, B. J., Wang, X. W., & Nichols, R. C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.128 · Cited by 40
Zhou, J., Wu, K., Gao, D., Zhu, G., Wu, D., Wang, X., Chen, Y., Du, Y., Song, W., Ma, Z., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.06.065 · Cited by 38
Von Hippel-Lindau Disease and the Eye
Karimi, S., Arabi, A., Shahraki, T., & Safi, S. (2020) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v15i1.5950 · Cited by 44
Chou, M. T.-H., Anthony, J., Bjorge, J. D., & Fujita, D. (2010) · Genes & Cancer · doi:10.1177/1947601910366719 · Cited by 37
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL -mutant renal carcinoma cells
Chintalapudi, M. R., Markiewicz, M., Kose, N., Dammai, V., Champion, K. J., Hoda, R. S., Trojanowska, M., & Hsu, T. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn019 · Cited by 37
Genetic Testing for Pheochromocytoma-associated Syndromes
Pawlu, C., Bausch, B., Reisch, N., & Neumann, H. P. H. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81749-4 · Cited by 36
APP induces neuronal apoptosis through APP-BP1-mediated downregulation of β-catenin
Chen, Y. Z. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000031447.05354.9f · Cited by 38
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma
Bukowski, R. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1403 · Cited by 36
Recent Insights into the Molecular Pathogenesis of Pheochromocytoma and Paraganglioma
Nakamura, E., & Kaelin, W. G. (2006) · Endocrine Pathology · doi:10.1385/ep:17:2:97 · Cited by 37
Self-citationJung, Y., Lee, S.-J., Yoon, M.-H., Ha, N., & Park, B.-J. (2012) · Cell Cycle · doi:10.4161/cc.22794 · Cited by 37
PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition
Gold, H. L., Wengrod, J., de Miera, E. V., Wang, D., Fleming, N. H., Sikkema, L., Kirchhoff, T., Hochman, T., Goldberg, J. D., Osman, I., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0422 · Cited by 36
Fliedner, S. M. J., Kaludercic, N., Jiang, X.-S., Hansíková, H., Hájková, Z., Sládková, J., Limpuangthip, A., Backlund, P. S., WESLEY, R. A., Martiniova, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040949 · Cited by 36
Ubiquitin domain proteins in disease
Madsen, L., Schulze, A., Seeger, M., & Hartmann‐Petersen, R. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s1 · Cited by 36
The hypoxic response and aging
Kaeberlein, M. R., & Kapahi, P. (2009) · Cell Cycle · doi:10.4161/cc.8.15.9126 · Cited by 40
The Daam2–VHL–Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation
Ding, X., Jo, J.-Y., Wang, C., Cristobal, C. D., Zuo, Z., Ye, Q., Wirianto, M., Lindeke-Myers, A., Choi, J. M., Mohila, C., et al. (2020) · Genes & Development · doi:10.1101/gad.338046.120 · Cited by 37
Yao, T. S., Wang, Q., Zhang, W., AiHong, B., & Zhang, J. (2016) · Oncology Letters · doi:10.3892/ol.2016.4573 · Cited by 33
Zhang, W., Li, L., Cai, L., Liang, Y., Xu, J., Liu, Y., Zhou, L., Ding, C., Zhang, Y., Zhao, H., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00724-5 · Cited by 32
Giacosa, S., Pillet, C., Séraudie, I., Guyon, L., Wallez, Y., Roelants, C., Battail, C., Evrard, B., Chalmel, F., Barette, C., et al. (2021) · Cancers · doi:10.3390/cancers13030576 · Cited by 46
Developmentally arrested structures preceding cerebellar tumors in von Hippel–Lindau disease
Shively, S. B., Falke, E., Li, J., Tran, M. G. B., Thompson, E. R., Maxwell, P. H., Roessler, E., Oldfield, E. H., Lonser, R. R., & Vortmeyer, A. O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.61 · Cited by 35
Role of diacylglycerol induced by hypoxia in the regulation of HIF-1α activity
Temes, E., Martín-Puig, S., Aragonés, J., Jones, D. R., Olmos, G., Mérida, I., & Landázuri, M. O. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.015 · Cited by 36
Molecular mechanisms of trophoblast survival: From implantation to birth
Jurisicova, A., Detmar, J., & Caniggia, I. (2005) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20053 · Cited by 42
Liu, X., Deng, H., Tang, J., Wang, Z., Zhu, C., Cai, X., Rong, F., Chen, X., Sun, X., Jia, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05008-z · Cited by 39
PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPEL–LINDAU EYE DISEASE
Krzystolik, K., Stopa, M., Kuprjanowicz, L., Drobek-Słowik, M., Cybulski, C., Jakubowska, A., Gronwald, J., Lubiński, J., & Lubiński, W. (2015) · Retina · doi:10.1097/iae.0000000000000707 · Cited by 33
Charbotel, B., Gad, S., Caïola, D., Béroud, C., Févotte, J., Bergeret, A., Ferlicot, S., & Richard, S. (2007) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-2-13 · Cited by 32
Somatic mutations in VHL germline deletion kindred correlate with mild phenotype
Wait, S. D., Vortmeyer, A. O., Lonser, R. R., Chang, D. T., Finn, M. A., Bhowmick, D. A., Pack, S., Oldfield, E. H., & Zhuang, Z. (2004) · Annals of Neurology · doi:10.1002/ana.10807 · Cited by 33
Jensen, R. L., Gillespie, D. L., House, P. A., Layfield, L. J., & Shelton, C. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.100.3.0488 · Cited by 32
Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors
Zhuang, Z., Frerich, J. M., Huntoon, K. M., Yang, C., Merrill, M. J., Abdullaev, Z., Pack, S., Shively, S. B., Stamp, G., & Lonser, R. R. (2014) · Scientific Reports · doi:10.1038/srep04102 · Cited by 33
The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells
Dakubo, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-11416-8_2 · Cited by 41
Robinson, C. M., Poon, B., Kano, Y., Pluthero, F. G., Kahr, W. H. A., & Ohh, M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0461 · Cited by 34
Guida, F. M., Santoni, M., Conti, A., Burattini, L., Savini, A., Zeppola, T., Caricato, M., Cascinu, S., Tonini, G., & Santini, D. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.07.006 · Cited by 31
Hypoxia Signaling in Vascular Homeostasis
Marsboom, G., & Rehman, J. (2018) · Physiology · doi:10.1152/physiol.00018.2018 · Cited by 38
The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer
Liu, X., Zurlo, G., & Zhang, Q. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_11 · Cited by 33
Friedrich, M., Heimer, N., Stoehr, R., Steven, A., Wach, S., Taubert, H. W., Hartmann, A., & Seliger, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-63403-y · Cited by 33
Champion, K. J., Guinea, M., Dammai, V., & Hsu, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6003 · Cited by 32
Role of the ubiquitin proteasome system in renal cell carcinoma
Corn, P. G. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s4 · Cited by 40
Hipoxia tumoral. Papel del factor inducible por hipoxia
Fraga, A. M., Ribeiro, R. J. T., & Medeiros, R. (2009) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(09)72891-8 · Cited by 50
When should genetic testing be performed in patients with neuroendocrine tumours?
O’Shea, T., & Druce, M. R. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9430-3 · Cited by 34
Genetic Aspects of Neurocutaneous Disorders
Jentarra, G. M., Snyder, S. L., & Narayanan, V. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.01.010 · Cited by 28
microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance
Zhang, W. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236094 · Cited by 30
Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management
Gomella, P. T., Linehan, W. M., & Ball, M. W. (2021) · Genes · doi:10.3390/genes12020261 · Cited by 32
Thirunavukkarasu, M., Selvaraju, V., Dunna, N. R., Foye, J. L. C., Joshi, M., Otani, H., & Maulik, N. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.03.005 · Cited by 29
Mosaicism in von Hippel‐Lindau disease: an event important to recognize
Santarpia, L., Sarlis, N. J., Santarpía, M., Sherman, S. I., Trimarchi, F., & Benvenga, S. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00122.x · Cited by 29
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
Roos, F. C., Roberts, A. M., Hwang, I. I. L., Moriyama, E. H., Evans, A. J., Sybingco, S. S., Watson, I. R., Carneiro, L. A. M., Gedye, C. A., Girardin, S. E., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000081 · Cited by 33
Guo, Y., Schoell, M. C., & Freeman, R. S. (2009) · Oncogene · doi:10.1038/onc.2009.35 · Cited by 34
The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma
Lei, G., Tang, L., Yu, Y., Bian, W., Yu, L., Zhou, J., Li, Y., Wang, Y., & Du, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115522 · Cited by 29
Shi, B., Zhang, H., Qiao, S., Bi, J., & Dai, S. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400187 · Cited by 28
Yi, Y., Mikhaylova, O., Mamedova, A. A., Bastola, P., Biesiada, J., Alshaikh, E. S., Levin, L., Sheridan, R. M., Meller, J., & Czyzyk-Krzeska, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3416 · Cited by 29
Kim, D. S., Choi, Y.-B., Han, B.-G., Park, S. Y., Jeon, Y. J., Kim, D.-H., Ahn, E.-R., Shin, J.-E., Lee, B. I., Lee, H. S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.183 · Cited by 30
Normoxic induction of cerebral HIF-1α by acetazolamide in rats: Role of acidosis
Xu, J., Peng, Z., Li, R., Dou, T., Xu, W., Gu, G., Liu, Y., Kang, Z., Tao, H., Zhang, J. H., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.008 · Cited by 31
Cho, H.-J., Ki, C., & Kim, J. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.1.77 · Cited by 28
Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau
Roberts, A. M., & Ohh, M. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f310de · Cited by 30
Bangiyeva, V., Rosenbloom, A., Alexander, A. E., Isanova, B., Popko, T., & Schoenfeld, A. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-229 · Cited by 30
An approach to cystic kidney diseases: the clinician's view
Kurschat, C. E., Müller, R., Franke, M., Maintz, D. C., Schermer, B., & Benzing, T. R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.173 · Cited by 30
Wu, K. L., Miao, H., & Khan, S. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00096.2007 · Cited by 30
Yao, L., Barontini, M., Niederle, B., Jech, M., Pfragner, R., & Dahia, P. L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2245 · Cited by 27
Von Hippel–Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma
Rasmussen, A., Nava-Salazar, S., Yescas, P., Alonso, E., Revuelta, R., Ortiz, I. P., Canizales‐Quinteros, S., Tusié-Luna, M. T., & López, M. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.104.3.389 · Cited by 26
Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Potti, A., & George, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050014 · Cited by 27
Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma
George, D. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2044 · Cited by 27
Rustum, Y. M., Chintala, S., Durrani, F. A., & Bhattacharya, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113378 · Cited by 28
Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells
Chauhan, R., Bhat, A. A., Masoodi, T., Bagga, P., Reddy, R. D., Gupta, A., Sheikh, Z. A., Macha, M. A., Haris, M., & Singh, M. K. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02163-7 · Cited by 31
Identification of 3 novel VHL germ-line mutations in Danish VHL patients
Dandanell, M., Friis-Hansen, L. J., Sunde, L., Nielsen, F. C., & Hansen, T. V. O. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-54 · Cited by 26
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Ricketts, C. J., Crooks, D. R., & Linehan, W. M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.016 · Cited by 29
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.